In androgen deprivation treatment of advanced prostate cancer, TRMT11 (tRNA methyltransferase 11) exhibited the strongest association with time to therapy failure (P < 0.001; FDR0.008; (40). This evidence concerns the gene TRMT11 and Familial prostate cancer.